Home > Insider Trading > Filing (0001209191-16-127335)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1131324	Genomic Health Inc	GHDX	Services-Medical Laboratories (8071)	770552594

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1337798	Bradley G Cole	301 Penobscot Drive Redwood City CA 94063	Coo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-06-09	4,800	$18.89	40,226	No	4	M	Direct
Common Stock	Acquisiton	2016-06-09	200	$18.89	40,426	No	4	M	Direct
Common Stock	Disposition	2016-06-09	4,800	$26.60	35,626	No	4	S	Direct
Common Stock	Disposition	2016-06-09	200	$27.22	35,426	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2016-06-09	4,800	$0.00	4,800	$18.89
Common Stock	Employee Stock Option (right to buy)	Disposition	2016-06-09	200	$0.00	200	$18.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
18,200		2016-11-30	No	4	M	Direct
18,000		2016-11-30	No	4	M	Direct

Footnotes

These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 7, 2016.
Represents weighted average sale price. Actual sale prices ranged from $26.20 to $27.11.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Includes an aggregate of 18,690 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Represents actual sale price.
The option became exercisable as to 25% of the shares on November 30, 2007, and became exercisable as to 1/48th of the shares each full month thereafter.